華潤醫藥(03320.HK)旗下華潤雙鶴收購天東製藥38.75%股權
華潤醫藥(03320.HK)旗下子公司華潤雙鶴公布,根據公司整體戰略規劃,為進一步豐富心腦血管抗凝領域產品、獲得抗凝領域技術平台,利用自有資金收購天東製藥38.75%的股權,收購價格為3.41億元。
公司指,投資併購是華潤雙鶴戰略重點舉措,尤其在現有存量業務受到帶量採購及疫情對診療觀念影響下,要實現躋身一流製藥企業目標,外延併購需大有作為。收購天東製藥38.75%的股權,將為雙鶴外延式發展提供支援,有利於實現華潤雙鶴戰略目標,有助於華潤雙鶴成功佈局肝素抗凝領域、獲得心腦血管抗凝領域不可缺少的藥品——肝素(原料藥及製劑),對公司規模擴張、產品結構調整、領域佈局、研發創新等方面發揮重要作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.